Clearside Biomedical (CLSD) announced that Health Canada has granted approval for XIPERE for suprachoroidal use in the treatment of uveitic macular edema, UME. XIPERE is approved for use in the United States, Canada, Australia, and Singapore and under regulatory review in China.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLSD:
- Snowflake initiated, Chipotle upgraded: Wall Street’s top analyst calls
- Clearside Biomedical downgraded to Neutral from Buy at H.C. Wainwright
- Clearside Biomedical downgraded to Neutral from Buy at Chardan
- Clearside Biomedical downgraded to Hold from Buy at Stifel
- Clearside Biomedical Downgraded to Hold Amid Strategic and Financial Uncertainties